Symbiotec Pharmalab IPO Day 3 Live: NII jumped 119.6% - Check analysts view and more
- Symbiotec Pharmalab IPO reached 4.94x subscription by end of Day 3 trading.
- NII (bHNI) category surged 119.6% intraday to 12.87x, driving overall momentum.
- Retail subscriptions jumped 73.3% to 4.80x, showing strong individual investor interest.
- QIB participation remained modest at 0.59x throughout the day.
- The IPO closes on 2026-08-27 with listing scheduled for 2026-09-01.
*this image is generated using AI for illustrative purposes only.
Symbiotec Pharmalab’s IPO raced ahead on Day 3, with cumulative subscriptions hitting 4.94x by 16:15 PM IST. The issue saw a sharp intraday surge, with the NII (bHNI) category jumping 119.6% in just one hour to reach 12.87x, while retail interest also picked up pace to 4.80x.
Subscription Status
The IPO gained significant momentum early on Day 3, breaking through the 4x mark within four hours of opening. While QIB participation remained stagnant at 0.59x, the Non-Institutional Investors (NII) segment, particularly large HNIs (bHNI), drove the bulk of the new demand. The bHNI category alone accounted for a massive increase from the morning snapshot, reflecting strong institutional confidence outside the QIB window.
| Category | Day 1 | Day 2 | Day 3 (Latest) | Total |
|---|---|---|---|---|
| QIB | 0.35x | 0.54x | 0.59x | 0.59x |
| NII (bHNI) | 1.56x | 4.03x | 12.87x | 12.87x |
| NII (sHNI) | 0.77x | 2.42x | 10.17x | 10.17x |
| Retail | 0.94x | 2.08x | 4.80x | 4.80x |
| Total | 0.79x | 1.83x | 4.94x | 4.94x |
Intra-day timeline on 26-08-2026
| Time (IST) | QIB | NII (bHNI) | Retail | Total |
|---|---|---|---|---|
| 11:15 | 0.55x | 5.86x | 2.77x | 2.47x |
| 12:15 | 0.55x | 7.33x | 3.24x | 2.98x |
| 13:15 | 0.55x | 8.92x | 3.68x | 3.56x |
| 14:15 | 0.56x | 10.51x | 4.11x | 4.13x |
| 15:15 | 0.58x | 11.81x | 4.47x | 4.59x |
| 16:15 | 0.59x | 12.87x | 4.80x | 4.94x |
The standout move was the 119.6% jump in NII (bHNI) subscriptions between 11:15 AM and 16:15 PM, pushing the total subscription up by 100.0% in that period. Retail investors also contributed significantly, adding 73.3% to their subscription tally.
About the Company
Symbiotec Pharmalab Limited is a research and development-driven pharmaceutical and biotechnology company founded in 2002. It operates across organic chemistry, biotechnology, and complex injectables platforms. The company holds a global leadership position in corticosteroid APIs with a 38.2% volume market share. Led by MD Anil Satwani, it serves over 200 customers across 40+ countries.
Financial Highlights
The company has shown consistent revenue growth over the last three years. Total equity increased significantly from ₹714.84 crores in FY24 to ₹1149.59 crores in FY26.
| Particulars | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue from Operations (₹ crores) | 716.25 | 751.55 | 869.15 |
| Total Profit (₹ crores) | 100.06 | 96.79 | 109.90 |
| Total Equity (₹ crores) | 714.84 | 814.71 | 1149.59 |
Revenue grew by 15.6% year-on-year in FY26, while profit before tax rose to ₹153.36 crores.
Objects of the Issue
- Prepayment and/or repayment of outstanding borrowings: ₹112.50 crores
- General corporate purposes: Balance net proceeds
Risk Factors
- High Revenue Concentration in APIs: 96.07% of revenue in FY26 came from API sales.
- Regulatory Compliance Risks: Recent US FDA inspections resulted in Form 483 observations.
- Customer Concentration Risk: Top ten customers accounted for 57.59% of product sales in FY26.
Key Dates
- Close Date: 2026-08-27
- Allotment Date: 2026-08-28
- Listing Date: 2026-09-01
How might the significant disparity between QIB (0.59x) and NII (12.87x) subscription levels impact the stock's price volatility in the first week of listing?
Given the recent US FDA Form 483 observations, what specific remediation steps has Symbiotec outlined to ensure regulatory compliance before listing?
Will the company's heavy reliance on API sales (96% of revenue) expose it to greater margin compression risks amid global raw material price fluctuations?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
